- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Genovis AB (GENOb)
Track the Genovis AB share price today and view real-time GENOb share price data, including charts, technicals, and key financials. View the GENOb premarket stock price ahead of the market session or assess the after hours quote. Explore GENOb stock price movements, trading volume, and market activity across the ST exchange.
What Is the Genovis AB Stock Price Today?
The Genovis AB stock price today is 21.500.
What Is the Stock Symbol for Genovis AB?
The stock symbol for Genovis AB is ""GENOb.""
What Stock Exchange Does Genovis AB Trade On?
Genovis AB is listed and trades on the Stockholm stock exchange.
Is Genovis AB a Good Stock to Buy?
Determining whether Genovis AB or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GENOb quote. (ISIN: SE0002485979)
What Is the Genovis AB Stock Price Today?
The Genovis AB stock price today is 21.500.
What Is the Stock Symbol for Genovis AB?
The stock symbol for Genovis AB is ""GENOb.""
What Stock Exchange Does Genovis AB Trade On?
Genovis AB is listed and trades on the Stockholm stock exchange.
Is Genovis AB a Good Stock to Buy?
Determining whether Genovis AB or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GENOb quote. (ISIN: SE0002485979)
21.500
+0.400(+1.90%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
20.800
21.600
52 wk Range
15.640
25.650
Unusual trading volume
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
20.80021.600
52 wk Range
15.64025.650
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
GENOb Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
33.000
Upside
+53.49%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a high earnings multiple
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 33.000
(+53.49% Upside)
Earnings
Latest Release
23/07/2026
EPS / Forecast
0.02 / 0.06
Revenue / Forecast
34.3M / 35.13M
Compare GENOb to Peers and Sector
Metrics to compare | GENOb | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGENObPeersSector | |
|---|---|---|---|---|
P/E Ratio | 69.4x | 14.8x | −0.4x | |
PEG Ratio | −2.80 | 0.30 | 0.00 | |
Price/Book | 4.6x | 3.0x | 2.6x | |
Price / LTM Sales | 10.4x | 3.4x | 3.1x | |
Upside (Analyst Target) | 56.4% | 10.7% | 49.0% | |
Fair Value Upside | Unlock | −8.1% | 7.1% | Unlock |
Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisREX, a protease that digests proteins C-terminally of arginine residues. In addition, the company offers OmniGLYZOR, a mixture of immobilized enzymes; PNGase F, a glycoamidase; OpeRATOR, an O-glycan-specific protease; ImpaRATOR, an O-glycan-dependent protease; OglyZOR, an endoglycosidase; SialEXO, a sialidase product; FucosEXO, a mix of a-Fucosidases; GalactEXO, a ß-Galactosidase mix; GalNAcEXO, an a-N-Acetylgalactosaminidase; and GlycOCATCH, an affinity resin. Further, it provides GlycINATOR (EndoS2), an IgG-specific endoglycosidase; IgGZERO (EndoS), an IgG-specific endoglycosidase; Anti-FabRICATOR (Anti-IdeS), a family of antibody products; and Anti-FabRICATOR Z (Anti-IdeZ), a goat polyclonal antibody, as well as SEQURNA RNase Inhibitor Thermostable. Additionally, the company offers antibodies, proteins, antigens, kits, and cell culture products; bioprocess and gene therapy services; and services, such as SmartEnzymes fragmentation and conjugation, antibody LC-MS analysis, and customized antibody services. It serves biotech and pharmaceutical, contract research, and contract manufacturing companies. The company was founded in 1999 and is headquartered in Kävlinge, Sweden.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Genovis AB (GENOb) Stock Price Today?
The Genovis AB stock price today is 21.500 SEK.
What Stock Exchange Does Genovis AB Trade On?
Genovis AB is listed and trades on the Stockholm Stock Exchange.
What Is the Stock Symbol for Genovis AB?
The stock symbol for Genovis AB is "GENOb."
What Is the Genovis AB Market Cap?
As of today, Genovis AB market cap is 1.420B SEK.
What Is Genovis AB's Earnings Per Share (TTM)?
The Genovis AB EPS (TTM) is 0.310.
When Is the Next Genovis AB Earnings Date?
Genovis AB will release its next earnings report on 10/11/2026.
From a Technical Analysis Perspective, Is GENOb a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Genovis AB Stock Split?
Genovis AB has split 10 times.
How Many Employees Does Genovis AB Have?
Genovis AB has 42 employees.
What is the current trading status of Genovis AB (GENOb)?
As of 03/09/2026, Genovis AB (GENOb) is trading at a price of 21.500 SEK, with a previous close of 21.100 SEK. The stock has fluctuated within a day range of 20.800 SEK to 21.600 SEK, while its 52-week range spans from 15.640 SEK to 25.650 SEK.
What Is Genovis AB (GENOb) Price Target According to Analysts?
The average 12-month price target for Genovis AB is 33.000 SEK, with a high estimate of 38 SEK and a low estimate of 28 SEK. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +53.49% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.